IPO, Metsera

Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such treatments.
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist.
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut this year.
Obesity drug developer Metsera sets terms for $275M IPO
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it ...
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
Metsera, Inc IPOs Tomorrow, Here's What You Need To Know
Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
FierceBiotech6d
‘A really rational IPO environment’: What does it takes for a biotech to go public now?
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
devdiscourse2d
From Drug Approvals to Global Health Funding: Key Updates in Health Sector
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO
Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...